Inventor · disambiguated record
Klarisa Rikova
Also filed as: RIKOVA KLARISA
28 granted patents·28 pending applications·73 citations·filing 2005–2025
96Inventor score
Files withCELL SIGNALING TECHNOLOGY INC28BLUEFIN BIOMEDICINE INC15RIKOVA KLARISA7POLAKEWICZ ROBERTO3CELL SIGNALING TECHNOLGY INC1
Top patents by PatentIndex Score
56 records- 0195US7700339B2Gene defects and mutant ALK kinase in human solid tumorsCELL SIGNALING TECHNOLOGY INC·Filed 2007·Granted Apr 20, 2010·22 cites·15 claims
- 0293US12138314B2Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0393US12138313B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0492US8232060B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2009·Granted Jul 31, 2012·6 cites·60 claims
- 0590US8481279B2Methods of treating lung cancer using inhibitors anaplastic lymphoma kinaseRIKOVA KLARISA·Filed 2012·Granted Jul 9, 2013·6 cites·24 claims
- 0690US8288102B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2010·Granted Oct 16, 2012·5 cites·40 claims
- 0789US11702481B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Jul 18, 2023·3 cites·19 claims
- 0889US11312769B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Apr 26, 2022·4 cites·14 claims
- 0989US8377642B2Gene defects and mutant ALK kinase in human solid tumorsCELL SIGNALING TECHNOLOGY INC·Filed 2010·Granted Feb 19, 2013·5 cites·36 claims
- 1088US11981732B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 14, 2024·1 cites·19 claims
- 1188US11634486B2Anti-SEZ6L2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Apr 25, 2023·3 cites·4 claims
- 1283US12491256B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2023·Granted Dec 9, 2025·0 cites·18 claims
- 1383US8168383B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2009·Granted May 1, 2012·5 cites·7 claims
- 1482US12473358B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 18, 2025·0 cites·19 claims
- 1582US11434303B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Sep 6, 2022·1 cites·12 claims
- 1682US9523130B2Methods of treating non-small cell lung carcinoma (NSCLC)CELL SIGNALING TECHNOLOGY INC·Filed 2016·Granted Dec 20, 2016·1 cites·29 claims
- 1780US9988688B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2015·Granted Jun 5, 2018·1 cites·15 claims
- 1880US8486645B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2012·Granted Jul 16, 2013·2 cites·12 claims
- 1979US2025092132A1Anti-ilt3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Application pending·0 cites
- 2077US11505833B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2020·Granted Nov 22, 2022·0 cites·10 claims
- 2176US12296006B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 13, 2025·0 cites·14 claims
- 2276US11267886B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Mar 8, 2022·1 cites·13 claims
- 2375US2023331839A1Anti-sez6l2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2023·Application pending·0 cites
- 2474US7807789B2Reagents for the detection of protein phosphorylation in EGFR-signaling pathwaysCELL SIGNALING TECHNOLOGY INC·Filed 2007·Granted Oct 5, 2010·1 cites·6 claims
- 2573US12110326B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted Oct 8, 2024·0 cites·22 claims
- 2673US10870892B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2018·Granted Dec 22, 2020·0 cites·12 claims
- 2773US2025319180A1Anti-ly6h antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2025·Application pending·0 cites
- 2870US10955416B2Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2018·Granted Mar 23, 2021·0 cites·9 claims
- 2970US8466160B2Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alphaRIKOVA KLARISA·Filed 2010·Granted Jun 18, 2013·1 cites·10 claims
- 3069US7932044B2Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-αCELL SIGNALING TECHNOLOGY INC·Filed 2005·Granted Apr 26, 2011·2 cites·13 claims
- 3167US2018156802A1Methods of treating lung cancer by administration of an alk inhibitorCELL SIGNALING TECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 3262US2014134640A1Gene Defects And Mutant ALK Kinase In Human Solid TumorsCELL SIGNALING TECHNOLOGY INC·Filed 2013·Application pending·0 cites
- 3361US2013209452A1Gene defects and mutant alk kinase in human solid tumorsRIKOVA KLARISA·Filed 2012·Application pending·0 cites
- 3460US7977462B2Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Granted Jul 12, 2011·1 cites·2 claims
- 3560US2016193208A1Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-alphaCELL SIGNALING TECHNOLOGY INC·Filed 2015·Application pending·0 cites
- 3659US2013266965A1Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHACELL SIGNALING TECHNOLOGY INC·Filed 2013·Application pending·0 cites
- 3759US2010216718A1Cancer Classification and Methods of UseCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 3854US2015185220A1Cancer classification and methods of useCELL SIGNALING TECHNOLOGY INC·Filed 2014·Application pending·0 cites
- 3952US2009099340A1Reagents for the detection of protein phosphorylation in carcinoma signaling pathwaysCELL SIGNALING TECHNOLOGY INC·Filed 2007·Application pending·0 cites
- 4050US2010304406A1Protein Phosphorylation by Serine/Threonine Kinases in Insulin Signaling PathwaysCELL SIGNALING TECHNOLOGY INC·Filed 2009·Application pending·0 cites
- 4148US2011130547A1Reagents For The Detection Of Protein Phosphorylation In EGFR Signaling PathwaysCELL SIGNALING TECHNOLOGY INC·Filed 2010·Application pending·0 cites
- 4247US2011105732A1Reagents for the Detection of Protein Phosphorylation in Carcinoma Signaling PathwaysCELL SIGNALING TECHNOLOGY·Filed 2011·Application pending·0 cites
- 4345US2008014598A1Phospho-specific antibodies to pi3k regulatory subunit and uses thereofCELL SIGNALING TECHNOLOGY INC·Filed 2007·Application pending·0 cites
- 4444US2009258442A1Reagents for the detection of protein phosphorylation in carcinoma signaling pathwaysCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 4544US2009305297A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 4643US2009053831A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 4743US2010093000A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 4843US2010120055A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2007·Application pending·0 cites
- 4942US2010151495A9Reagents for the detection of protein phosphorylation in carcinoma signaling pathwaysCELL SIGNALING TECHNOLGY INC·Filed 2008·Application pending·0 cites
- 5040US2010129929A1Tyrosine Phosphorylation SitesPOLAKEWICZ ROBERTO·Filed 2007·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →